Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. - Wikidata - awgldk - TriplyDB

Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.

Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.

http://www.wikidata.org/entity/Q38263490

about

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation Optimizing antiviral agents for hepatitis B management in malignant lymphomas.A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study.Selective interaction of PEGylated polyglutamic acid nanocapsules with cancer cells in a 3D model of a metastatic lymph node Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study.

P2860

Q26746486-C1200C17-2081-4D68-858C-123548C5F913 Q35999110-4E5EA557-11BC-4877-A5C5-92ADD1F34221 Q36782745-C1F33DBC-C1BE-44BC-A956-94CF2C59694E Q37666948-CFFE2A1C-5D8C-4894-A8F7-94111317FEFC Q38664705-C6CF4FB2-6FAA-421B-8E56-C299AB2480F4 Q38856824-B5799485-6FD5-4B7E-8D66-7142C99AD24E Q39010415-4AD53D15-0053-4595-AE6B-40184978906A Q39264020-6E82DE30-4F0D-481A-A540-C9258F201D76 Q39532967-51CF512D-2D15-4471-A199-8B1F6A5ED7DC Q40195372-54AC8E70-7430-407A-A4C0-FC94627999A0 Q40511245-ABBCF6EE-B87B-446D-BC89-15EBA2929CB1 Q41930205-7B636AE8-01FC-4AF0-834D-12F687E0F999 Q42122391-D5A63A74-4B32-4C8D-B0E9-C31417593135 Q47116736-8775AC3E-59D9-41E3-8675-D06F2CE247EA

P2860

Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.

http://www.wikidata.org/entity/Q38263490

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.

@en

type

label

Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.

@en

prefLabel

Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.

@en

P1433

Q38263490-03497314-ACAF-4EED-8DFF-0C22BCF08397

P1476

Q38263490-18ACC5EE-F01F-4DC2-860D-1EC19192B7E5

P2093

Q38263490-027A9BB6-0D55-4A8E-8460-14CA4B737857

P2860

Q38263490-014DF770-C71B-45E9-AC46-CBF6535499B2

Q38263490-0962320A-9D89-49C5-A1CC-D26D8EA0E2B4

Q38263490-1059FD28-288A-4F22-BD3D-701F8C7F20ED

Q38263490-1D61F533-277F-4D26-8CAA-1366AAA6B871

Q38263490-2F3322BB-CC5B-47B5-A12E-7937DB2368A0

Q38263490-2F692790-141F-4FED-A2DA-31F22FF0F588

Q38263490-31564622-F38B-4001-ADA0-C06A216CB4CB

Q38263490-358E65CC-44A4-4347-95BE-987A25C2234E

Q38263490-419985AA-7932-40E9-8133-3D8255DC1166

Q38263490-49C11AC9-D00D-4845-8F1C-C71EEE0C7AE5

P304

Q38263490-AEA7B5FF-72C7-4B04-9AD0-97FF4542E53E

P31

Q38263490-BCEED876-720F-457A-A743-1AC4793B15F2

P356

Q38263490-F9F8447D-7431-444F-B111-1D4E9D5C1276

P407

Q38263490-9663D552-AB55-4833-86A2-C7454E646FB1

P478

Q38263490-577D0259-5E13-4758-902A-5ED571D03061

P577

Q38263490-47CF723C-91C7-44EE-AB72-875FD1EA3376

P698

Q38263490-115283B0-5B67-4EAC-8FEF-F8625030E5AD

P921

Q38263490-A7CCEB1A-FB13-4D46-AD9E-C8E901C06429

P356

P1433

Clinical Infectious Diseases

P1476

Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.

@en

P2093

Vicki A Morrison

http://www.w3.org/2001/XMLSchema#string

P2860

Current trends in management of hepatitis B virus reactivation in the biologic therapy era

Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101

P304

S360-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIU592

http://www.w3.org/2001/XMLSchema#string

P407

P478

59 Suppl 5

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25352632

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression